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Abstract 
Background: Insulin-like growth factor (IGF)-1 has been implicated in the pathogenesis of 
Alzheimer’s disease (AD). 
Methods: We compared the level of circulating total and bioavailable IGF-1, by simultaneous 
measurements of IGF-1 and IGF binding protein (IGFBP)-3, between 87 patients diagnosed 
with AD and 126 age and sex matched control subjects without cognitive impairment. Blood 
samples were collected and IGF-1 and IGFBP-3 measured by ELISA. Subjects were also 
genotyped for apolipoprotein E. 
Results: Total circulating IGF-1 levels were significantly raised in the AD group as compared 
to the control group (p=0.022). There was no significant difference in the circulating level of 
IGFBP-3 between the two groups. When the IGF-1 levels were ratioed against IGFBP-3 
levels as an indicator of unbound, bioavailable circulating IGF-1, there was a significant 
increase in the molar IGF-1:IGFBP-3 ratio in the AD subjects (0.181 ± 0.006) as compared to 
the controls (0.156 ± 0.004) (p<0.001). Logistic regression analysis revealed that an increase 
in the IGF-1:IGFBP-3 molar ratio increased the risk of AD significantly. 
Conclusion: The results of increased total and free circulating IGF-1 support the hypothesis 
that in its early stages late-onset AD reflects a state of resistance to IGF-1. 
 
Key words: Alzheimer’s, insulin-like growth factor-1, insulin-like growth factor binding 
protein-3, apolipoprotein E, insulin resistance. 
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Introduction 
 Alzheimer’s disease (AD) is the most prevalent form of dementia and understanding the 
factors which influence the pathophysiology of the disease is essential for impacting on 
incidence and defining new therapeutic strategies. Insulin-like growth factor (IGF)-1 
modulates growth and metabolic function in the brain, enhances neuronal survival and exerts 
neurotrophic activities in the hippocampus, which is involved in learning and memory [10, 
11]. At a cellular level, disruption of IGF-1 input lowers neuronal resistance to amyloid β 
(Aβ) peptide toxicity, increases cellular susceptibility to cell death signals, enhances 
phosphorylation of tau and leads ultimately to accumulation of Aβ in the brain [5]. Aβ, which 
is proteolytically cleaved from the larger amyloid β-protein precursor (AβPP) [30], is the key 
constituent of the amyloid plaque and hyperphosphorylation of tau is integral to the formation 
of neurofibrillary tangles, both of which are diagnostic of AD pathologically.  
 Although IGF-1, its receptor and binding proteins are present and locally produced in the 
brain [27], IGF-1 is actively transported across the blood-brain barrier, and therefore changes 
in circulating IGF-1 can lead to changes in IGF-1 input to the brain [4]. The bioavailability 
and bioactivity of IGF-1 is regulated by six IGF binding proteins (IGFBPs) and several 
IGFBP-proteases [7, 8]. Quantitatively the most important binding protein in the circulation is 
IGFBP-3 which binds more than 80% of the circulating IGF-1 [15]. Thus measurement of 
circulating IGFBP-3 levels, in addition to IGF-1 levels, allows the amount of bioavailable 
IGF-1 to be determined [16, 23]. Although other studies have measured circulating IGF-1 
levels in AD subjects as compared to control subjects, the results have been conflicting with 
one showing an increase [29] and two a decrease [22, 32] in IGF-1 levels in AD. However, 
none of these studies measured the circulating levels of IGFBP-3 which would reflect the 
amount of bioavailable IGF-1. This lack of measurement of bioavailable IGF-1 was identified 
as a potential limitation with these studies [32]. Therefore, the present study was designed to 
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compare the level of circulating total and bioavailable IGF-1, by simultaneous measurements 
of IGF-1 and IGFBP-3, between patients with late-onset, sporadic AD and age-matched 
controls without dementia. 
 
Materials and Methods 
Subjects 
 Two hundred and thirteen elderly subjects were enrolled for the purposes of this study. 
These subjects consisted of 87 patients diagnosed with AD and 126 age and sex matched 
control subjects without cognitive impairment. AD patients were recruited through memory 
clinics in Leeds and Dewsbury (West Yorkshire, England). Control subjects were recruited 
through the Leeds Family Health Services Authority, day hospitals and elderly medicine 
outpatient clinics within the Leeds area. All participants were of European Caucasian 
extraction and gave written informed consent (assent from relatives of the AD patients was 
given where appropriate) according to a protocol approved by the Leeds (East) Research 
Ethics Committee. Diagnosis of probable AD was made in accordance with international 
diagnostic criteria (National Institute of Neurological and Communicative Disorders and 
Stroke-Alzheimer’s Disease and Related Disorders Association Work Group; NINCDS-
ADRDA) [18]. All patients and control subjects underwent a standardized clinical evaluation 
which included medical history, anthropometric measurements and cognitive function 
assessment (Mini-Mental State Examination; MMSE and Modified Mini-Mental State 
examination; 3MS) [12, 28]. Demographic and clinical profiles of the subjects participating in 
this study are summarized in table 1. 
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Assays 
 Blood samples were collected between 8 am and noon after an overnight fast in lithium 
heparin on ice, centrifuged at 4°C at 2997g for 30 min and the plasma samples stored at -40°C 
until analysis. Enzyme-linked immunosorbent assay (ELISA) kits were used to measure 
insulin (Biosource, Nivelles, Belgium), total IGF-1 and IGFBP-3 (R&D Systems, Oxford, 
UK).   According to the manufacturer’s data sheets, the minimum detection limit for the IGF-
1 assay was 0.026 ng/ml (3.42 pM) and for the IGFBP-3 assay was 0.05 ng/ml (1.72 pM), and 
the IGF-1 assay does not detect IGF-2, insulin, IGFBP-2, -3 or -4, and the IGFBP-3 assay 
does not detect IGF-1 or -2, IGFBP-1, -2, -4, -5 or -6.  The apolipoprotein E (ApoE) genotype 
was determined by polymerase chain reaction as described previously [6]. 
 
Statistical Analysis 
 All statistical analyses were performed using SPSS for windows version 12.0. Distribution 
of variables was tested for skewness using the Kolmogrov-Smirnov test. Normal data are 
presented as mean and standard error of the mean; non-parametric data are presented as 
median and range. The unpaired Students t-test was used to compare mean values of normally 
distributed data; the Mann-Whitney U-test was used to compare non-parametric data. 
Differences in categorical data (expressed as percentages) groups were assessed using the chi-
squared test. Logistic regression analysis was used to investigate factors contributing to the 
risk of AD. 
 
Results 
 There were no significant differences between the AD group and the control group in 
terms of age, gender, alcohol intake (past or present), education (years of schooling or 
university attendance), prevalence of diabetes mellitus, prevalence of cerebrovascular or 
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cardiovascular disease, fasting blood sugar, fasting plasma insulin or insulin resistance as 
defined by the homeostasis model assessment (HOMA) [31] (Table 1). HOMA is a validated 
standard method of assessing insulin resistance using glucose and insulin concentrations, 
calculated by dividing the product of fasting plasma insulin concentration and fasting plasma 
glucose concentration by 22.5 [31].  The low prevalence of diabetes mellitus in the AD 
subjects and control group (Table 1) is very similar to general population figures quoting 
prevalence to be 3.45% in England [19].    AD subjects were significantly shorter in stature 
than the control group (p=0.038), had significantly smaller head circumference (p=0.039) and 
were significantly lighter in weight (p<0.001) than control subjects (Table 1). Body mass 
index (BMI) was significantly lower in the AD subjects as compared to the control group 
(p=0.001) (Table 1).  There was a significantly greater proportion of subjects with at least one 
copy of the ApoE4 allele in the AD group (p<0.001) (Table 1). 
 Comparison of total plasma IGF-1 between AD subjects and control subjects revealed it to 
be significantly raised in the AD group as compared to the control group (p=0.022) (Table 1). 
There was no significant difference in the plasma level of IGFBP-3 between the two groups. 
When the IGF-1 was ratioed against IGFBP-3 as an indicator of unbound, bioavailable 
circulating IGF-1 [16], there was a significant increase in the IGF-1:IGFBP-3 molar ratio in 
the AD subjects (0.181 ± 0.006) as compared to the controls (0.156 ± 0.004) indicating a 
greater amount of circulating bioavailable IGF-1 in the AD subjects (p<0.001) (Fig 1).   
 Logistic regression analysis was performed to look for independent associations between 
particular parameters and the risk of AD (Table 2). Of the factors in the model, the presence 
of an ApoE4 allele and also an increase in the IGF-1:IGFBP-3 molar ratio each increased the 
odds of AD significantly. In particular, for an increase of one standard deviation of IGF-
1:IGFBP-3 molar ratio, the estimated odds ratio of being a patient with AD was 1.90 
(p=0.001). No interaction between ApoE4 status and IGF-1:IGFBP-3 molar ratio was 
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detected and there was no significant difference in IGF-1:IGFBP-3 molar ratio when the 
subjects were grouped based on ApoE4 status. Although weight was also significantly 
associated, ischaemic heart disease, cerebrovascular disease, diabetes, smoking status and 
plasma insulin were not associated with the risk of AD (Table 2). There was no correlation 
between MMSE and IGF-1, IGFBP-3 or IGF-1:IGFBP-3 molar ratio in the AD group.      
 
Discussion 
 In this study, the primary findings were that circulating total IGF-1 was raised in late-
onset, sporadic AD subjects as compared to controls. Furthermore, the IGF-1:IGFBP-3 ratio, 
indicative of bioavailable IGF-1, was raised significantly in the AD subjects as compared to 
control subjects. Secondary findings included significant associations between stature, head 
circumference, weight, BMI, ApoE4 allele and AD consistent with previous studies [1, 2, 21, 
26]. There was no significant difference between the groups in terms of plasma insulin 
measurements and insulin resistance as measured by HOMA [31].  Although other studies 
have shown plasma insulin to be raised in AD [3, 9, 20], these studies included smaller 
numbers of subjects (12-25 AD patients; 14-66 controls) and also excluded diabetic subjects. 
A larger study found cognitive impairment with subcortical features to be associated with 
biochemical and clinical features of the insulin resistance syndrome [13], however, this work 
was not limited to AD. 
 Our data are consistent with a previous small study with 10 Caucasian sporadic AD 
subjects (age range 63-74 years with probable AD according to the NINCDS-ADRDA criteria 
and mean MMSE ± S.D. 15 ± 9) and 10 controls (age range 65-83 years) which found 
circulating total IGF-1 to be raised in the AD group [29]. Increased circulating IGF-1, both 
total and bioavailable, is consistent with the hypothesis that late-onset AD may reflect a state 
of resistance to IGF-1 signalling, with the primary pathogenic event being the loss of 
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sensitivity to IGF-1 action [5], possibly due to reduced receptor expression or function in the 
AD brain [25]. In an attempt to overcome this resistance to IGF-1 signalling, circulating IGF-
1 increases. Although it has been suggested that the IGF-1 resistance in late-onset, sporadic 
AD may either originate from prior insulin resistance or lead to the development of insulin 
resistance [5, 14], there was no difference in measures of peripheral insulin resistance 
between the AD subjects and controls in our study. 
 In contrast to the increase in IGF-1 observed in our study and that of Tham et al. [29], 
reduced circulating total IGF-1 was observed in a study involving 106 Japanese sporadic AD 
subjects (mean age 79 years with probable AD according to NINCDS-ADRDA criteria and 
mean MMSE ± S.D. 11 ± 7) compared with 227 control subjects (mean age 76 years) [32]. 
One possible explanation for the observed difference between our study and that of Watanabe 
et al. [32] is that in the earlier stages of AD IGF-1 is raised, as seen in our study where the 
mean MMSE score was 21, whereas in the later stages of the disease IGF-1 decreases, as seen 
in the study by Watanabe et al. [32] where the mean MMSE score was 11. Although it should 
be noted that we did not observe any correlation between either total or free circulating IGF-1 
and MMSE score. 
 Circulating total IGF-1 was reported to be reduced in 5 familial AD subjects (mean age 
60.8 years with probable AD according to NINCDS-ADRDA criteria) compared with 10 
controls (mean age 55.8 years) [22]. However, all the patients in this study carried the 
Swedish AβPP 670/671 mutation that causes early onset AD. It has been suggested that 
alterations in IGF-1 in this case may be due to a greater demand for IGF-1 neuroprotection 
due to the primary pathogenic event (the mutation in AβPP) in this case causing an increase in 
the production of the neurotoxic Aβ peptide [5].  
  In conclusion, the increased circulating IGF-1 observed in the present study provides 
evidence that in the early stages late-onset, sporadic AD may reflect a state of resistance to 
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IGF-1 signalling. At what stage in the dementia process resistance to IGF-1 develops and 
whether this state predates the onset of cognitive impairment have yet to be determined. 
However, it should be emphasised that the results presented here refer to plasma IGF-1 levels 
and, as cerebrospinal fluid samples were not taken, we cannot be certain that these levels of 
IGF-1 would be replicated in the brain and thus whether blood vessels, brain parenchymal 
cells or both are IGF-1 resistant.  Also as higher total IGF-1 has also been associated with 
better cognitive performance and lower risk of cognitive decline in older individuals [17, 23, 
24], the measurement of circulating IGF-1 is unlikely to be a useful biomarker to screen for 
the onset of AD. If in the early stages late-onset, sporadic AD is indeed a state of resistance to 
IGF-1 signalling, this may explain why MK-0677, a compound that induces secretion of IGF-
1 and increased circulating IGF-1 by 60%, failed to alter cognitive function in a double-blind 
trial in 563 AD patients with baseline MMSE scores between 14 and 26 
(http://www.alzforum.org/new/detail.asp?id=1458). Rather, it may be that therapeutics that 
increase the sensitivity of cells to IGF-1 would hold greater potential in the pharmacological 
treatment of patients in the early stages of AD. 
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Table 1. Clinical and biochemical characteristics of study subjects 
Characteristic AD (n=87) Control (n=126) p value 
 
Male % 
 
47 47 NS 
Age (yrs) 
 
78.7 ± 0.7 78.8 ± 0.6 NS 
MMSE score 
 
21 (7-27) 29 (27-30) <0.001 
3MS score 63 (12-88) 
 
97 (82-100) 
 
<0.001 
 
Current smoker % 
 
2.3 7.9 NS 
Alcohol current 
(units/week) 
0 (0-28) 
 
2 (0-60) NS 
 
Alcohol past (max. 
units/week) 
2 (0-80) 4.5 (0-140) 
 
NS 
 
Diabetes mellitus % 
 
4.6 4.1 NS 
Ischaemic heart 
disease % 
17.2 26.2 NS 
Cerebrovascular 
disease % 
8.0 11.9 NS 
BMI (kg/m2) 
 
24.9 ± 0.4 26.9 ± 0.4 0.001 
Weight (kg) 
 
66.4 ± 1.5 74.1 ± 1.3 <0.001 
Height (cm) 
 
163.1 ± 1.1 166.0 ± 0.9 0.038 
Head circumference 
(cm) 
56.0 (51.0-61.0) 
 
56.5 (52.0-62.0) 
 
0.039 
 
Schooling (years) 
 
10 (7-14) 
 
10 (7-14) 
 
NS 
 
University attendance 
(%) 
6.9 5.6 NS 
Apolipoprotein E4 
allele positive (%) 
64.4 19.8 <0.001 
Fasting plasma 
glucose (mmol/l) 
5.0 (3.8-12.8) 5.2 (4.2-8.9) NS 
Fasting plasma insulin 
(µIU/ml)* 
7.9 (3.3-44.7) 8.0 (3.0-56.0) NS 
HOMA* 
 
1.8 (0.9-21.0) 1.8 (0.6-16.7) NS 
IGF-1 (nM) 
 
11.3 ± 0.3 10.3 ± 0.3 0.022 
IGFBP-3 (nM) 65.8 ± 2.1 68.7 ± 1.6 NS 
 
Data are shown as mean ± SEM or median (range). *Those taking synthetic insulin were 
excluded from the analysis. 
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Table 2. Association of IGF-1:IGFBP-3 ratio and other parameters with AD 
 
       
 
Parameter  Estimated  95% CI  p value 
    Odds ratio       
 
 
 
IGF-1:IGFBP-3 1.90*   1.30-2.79  0.001
molar ratio 
 
Age   1.03   0.97-1.09  0.316   
 
Gender  2.26   0.87-5.92  0.096 
 
Height   0.96   0.92-1.01  0.139 
 
Weight  0.96   0.92-0.99  0.008  
 
ApoE4 allele  8.10   3.89-16.87  <0.001 
 
Ischaemic  0.50   0.20-1.24  0.135 
heart disease 
 
Cerebrovascular 0.78   0.23-2.67  0.697 
disease 
 
Diabetes mellitus 1.00   0.21-4.70  0.997 
 
Smoking status 0.17   0.02-1.19  0.074 
 
Plasma insulin  1.05   0.99-1.12  0.096 
  
 
 
* Estimated Odds ratio for an increase of one standard deviation. 
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Figure 1. Plasma IGF-1:IG
Bars represent mean ± SEM
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